Tolerability demonstrated in thousands of patients1
- 24% of patients receiving Mysimba® and 12% of patients receiving placebo discontinued treatment because of an adverse reaction1
- The most frequent adverse reactions leading to discontinuation were nausea (Very Common), headache (Very Common), and vomiting (Very Common)1
- Common GI-related adverse reactions such as nausea and vomiting were generally transient in nature and resolved within 4 weeks for most patients.1-4
• very common: ≥1 in 10
• common: ≥1 in 100 to <1 in 10
• common: ≥1 in 100 to <1 in 10
General Nausea Tips
- Remind your patient to drink plenty of water
- Suggest that your patients take a small amount of dry toast with MYSIMBA
- Consider recommending an anti nausea medication
Note: The weight loss seen with Mysimba is independent of Nausea 4
References
- Mysimba 8 mg/90 mg prolonged-release tablets Summary of Product Characteristics available on medicines.ie or www.ema.europa.eu .
- Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595-605.
- Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19(1):110-120.
- Hong K, Herrmann K, Dybala C, Halseth AE, Lam H, Foreyt JP. Naltrexone/bupropion extended release-induced weight loss is independent of nausea in subjects without diabetes. Clin Obes. 2016;6(5):305-312.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions
IE-MYS-212(1), MYS-0454-001 01/26 DOP: January 2026
The information on this website is intended for Healthcare Professionals who reside in Ireland and Malta only.
Healthcare professionals who reside in Ireland are asked to report any suspected adverse events to: HPRA Pharmacovigilance via www.hpra.ie;
Adverse events should also be reported to Orexigen: +353 1800 849 099 or Currax.Ml@primevigilance.com.
Healthcare professionals who reside in Malta are asked to report any suspected adverse events to: the Malta Medicines Authority via http://medicinesauthority.gov.mt/adrportal or Vivian Corporation Ltd. via pv@viviancorp.com.
Adverse events should also be reported to Orexigen: +356 800 62176 or Currax.Ml@primevigilance.com.